ClinicalTrials.gov
public full text
Public Domain
Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver Failure
This randomized controlled trial evaluates whether oral N-acetylcysteine (NAC), given alongside standard supportive care, improves survival and reduces mortality in patients with non-acetaminophen-induced acute liver failure (ALF), compared to supportive care alone. Secondary objectives are to assess NAC's effect on length of hospital stay and improvement in liver function tests. Sixty-two adult patients (18-60 years) will be randomized 1:1 to NAC or control, with outcomes assessed at 28 days (survival/mortality) and day 4 (liver function tests).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Case for N-acetylcysteine in Dengue Associated Liver Injury: Time for Definitive Evidence#642539
- N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection#802454
- Comparison of Two sTRAtegies For the Non-Invasive Diagnosis of advanCed Liver Fibrosis in NAFLD#1044771
- Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)#1009110
- Prediction of acetaminophen-induced hepatotoxicity in acetylcysteine-treated patients using routine admission biomarkers#459900
Record · ID 1137470
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive